Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
BörsenkürzelSGHT
Name des UnternehmensSight Sciences Inc
IPO-datumJul 15, 2021
CEOBadawi (Paul)
Anzahl der mitarbeiter216
WertpapierartOrdinary Share
GeschäftsjahresendeJul 15
Addresse4040 Campbell Ave,
StadtMENLO PARK
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94025
Telefon14158890550
Websitehttps://www.sightsciences.com/
BörsenkürzelSGHT
IPO-datumJul 15, 2021
CEOBadawi (Paul)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten